1. Home
  2. PLBY vs CRDF Comparison

PLBY vs CRDF Comparison

Compare PLBY & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PLBY

PLBY Group Inc.

HOLD

Current Price

$1.80

Market Cap

159.5M

ML Signal

HOLD

Logo Cardiff Oncology Inc.

CRDF

Cardiff Oncology Inc.

HOLD

Current Price

$1.79

Market Cap

130.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PLBY
CRDF
Founded
1953
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Recreational Games/Products/Toys
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
159.5M
130.7M
IPO Year
2020
2012

Fundamental Metrics

Financial Performance
Metric
PLBY
CRDF
Price
$1.80
$1.79
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
4
Target Price
$3.00
$9.63
AVG Volume (30 Days)
749.7K
730.0K
Earning Date
05-14-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
87.50
27.37
EPS
N/A
N/A
Revenue
$120,928,000.00
$365,993.00
Revenue This Year
$9.17
N/A
Revenue Next Year
$7.10
N/A
P/E Ratio
N/A
N/A
Revenue Growth
4.13
49.61
52 Week Low
$0.93
$1.48
52 Week High
$2.75
$4.56

Technical Indicators

Market Signals
Indicator
PLBY
CRDF
Relative Strength Index (RSI) 59.64 55.72
Support Level $1.65 $1.51
Resistance Level $1.99 $2.05
Average True Range (ATR) 0.11 0.08
MACD 0.04 0.03
Stochastic Oscillator 81.91 84.48

Price Performance

Historical Comparison
PLBY
CRDF

About PLBY PLBY Group Inc.

Playboy Inc, formerly PLBY Group Inc connects consumers around the world with products, services, and experiences to help them look good, feel good, and have fun. PLBY Group serves consumers in four categories: Style and Apparel, Digital Entertainment and Lifestyle, Sexual Wellness, and Beauty and Grooming. It operates through three segments Direct-to-Consumer, Licensing, and Digital Subscriptions and Content. It generates revenue through the sales of products and content services to consumers.

About CRDF Cardiff Oncology Inc.

Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.

Share on Social Networks: